Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL516989

N.O=C(O)C(F)(F)C(F)(C(F)(F)F)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.50
ACLY P53396 2/20 0.39
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TET2 Q6N021 1/20 0.30
TP53 P04637 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9068682 0.97 THRB (0.52) THRBACLYALDH1A1L3MBTL1TET2
SCHEMBL28419714 0.82 THRB (0.59) THRBACLYALDH1A1L3MBTL1
Ammonia Solution, Strong SCHEMBL517121 0.82 THRB (0.59) THRBACLYALDH1A1L3MBTL1
SCHEMBL756867 0.80 THRB (0.56) THRBACLYTET2
Ammonia Solution, Strong SCHEMBL517312 0.80 THRB (0.64) THRBACLYTET2
SCHEMBL30772129 0.80 THRB (0.64) THRBACLYTET2
Ammonia Solution, Strong SCHEMBL28552766 0.80 THRB (0.55) THRBACLYALDH1A1L3MBTL1TET2
Ammonia Solution, Strong SCHEMBL28539482 0.79 THRB (0.53) THRBACLYALDH1A1L3MBTL1TP53
Ammonia Solution, Strong SCHEMBL28539481 0.79 THRB (0.53) THRBACLYALDH1A1L3MBTL1TP53
SCHEMBL5915248 0.79 THRB (0.62) THRBACLYALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487003-B2 Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids CXR BIOSCIENCES LIMITED (GB) 2013-07-16 US disclosed
US-20120029079-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LIMITED (GB) 2012-02-02 US disclosed
EP-2260842-A2 Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass CXR Biosciences Limited (GB) 2010-12-15 EP disclosed
US-20100240751-A1 Methods CXR BIOSCIENCES LIMITED 2010-09-23 US disclosed
EP-1359906-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LTD (GB) 2008-05-14 EP disclosed
EP-1875904-A1 Methods CXR BIOSCIENCES LIMITED (GB) 2008-01-09 EP disclosed
EP-1745779-A2 Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass CXR BIOSCIENCES LIMITED (GB) 2007-01-24 EP disclosed
US-20060052451-A1 Method ELCOMBE CLIFFORD R 2006-03-09 US disclosed
US-20050175639-A1 Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids CXR BIOSCIENCES LIMITED (GB) 2005-08-11 US disclosed
EP-1534260-A2 PERFLUORINATED FATTY ACIDS FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDAEMIA, CANCER AND INFLAMMATION CXR BIOSCIENCES LIMITED (GB) 2005-06-01 EP disclosed
WO-2004019927-A2 PERFLUORINATED FATTY ACIDS FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDAEMIA, CANCER AND INFLAMMATION CXR BIOSCIENCES LIMITED (SC 211745) (GB) 2004-03-11 WO disclosed
EP-1359906-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LIMITED (GB) 2003-11-12 EP disclosed
WO-2002066028-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LIMITED (GB) 2002-08-29 WO disclosed